



Asian Centre for Liver Diseases and Transplantation Limited

(formally known as Costarella Design Limited)
ABN 42 091 559 125

4 February 2010

ASX Online
Company Announcements Office
ASX Limited

ASX RELEASE

GROUP CHIEF OPERATING OFFICER AND GROUP FINANCIAL CONTROLLER APPOINTED

Asian Centre for Liver Diseases and Transplantation Limited ("ACL"; ASX: AJJ) is pleased to announce the appointments of Mr Cherinjit Kumar Shori as Group Chief Operating Officer, and of Mr Yeoh Meng Yau as Group Financial Controller ahead of the expansion of its operations into Vietnam, Malaysia and China.

Mr Cherinjit Kumar Shori

Mr Shori has more than 19 years' experience in the healthcare and hospitality industry. Most recently he was the Group Vice President/Deputy Chief Marketing Officer for Singapore-based Parkway Group Healthcare Pte Ltd, one of Asia's largest healthcare providers, where he developed new growth markets for Parkway over the past 10 years. Earlier, he held senior management positions with Sun Cruises, Sembawang Leisure (a subsidiary of Sembawang Corporation) and other companies. Mr Shori holds a Bachelor of Accountancy degree from Nanyang Technological University in Singapore and a Graduate Diploma in Marketing and Healthcare.

Mr Yeoh Meng Yau

Mr Yeoh is a Certified Public Accountant with more than 15 years' experience in finance and accounting. His career has included stints in several public-listed and privately owned companies involved in a wide range of businesses including construction, IT, investment and the service industry in Singapore, Malaysia and Australia. He is a non-practicing member of the Institute of Certified Public Accountants of Singapore, Fellow Member of the Association of Chartered Certified Accountants and a Chartered Accountant registered with the Malaysian Institute of Accountants.

ACL Executive Chairman, Dato' Dr Tan Kai Chah, said: "We are very excited about the appointments of Cherinjit and Meng Yau which are part of our commitment to increase the depth of our management team. The experience that they bring from their respective fields of expertise will help drive the company as it embarks on its growth strategy."

Mr Shori commented: "ACL is a unique company with tremendous potential to expand into new growth markets in Asia. It is exciting to join it at this important phase of its development."

Mr Yeoh said: "I am looking forward to playing an active role as part of a team that takes the company to the next level, to increase value for shareholders."

-END-

For and on behalf of the Board



DARIO NAZZARI
Company Secretary

About Asian Centre for Liver Diseases and Transplantation

Asian Centre for Liver Diseases & Transplantation Ltd (ASX:AJJ), founded in 1994, started trading on the Australian Securities Exchange in September 2009. The company's centre at Gleneagles Hospital, Singapore, is the largest private liver transplant and liver disease treatment facility in Asia, treating people from throughout the world. AJJ is progressing plans to establish centres in Vietnam, Malaysia and China to meet the growing demand in emerging markets.

The incidence of liver cancer has doubled in the past two decades and continues to increase due to hepatitis B and hepatitis C, alcoholism and fatty liver disease. AJJ has specialist skill in liver transplants from live donors, such as relatives, as the liver is the only organ that can regenerate.

For further information, please visit www.asianlivercentre.com.sg

Australia contact:

Mr. Dario Nazzari, Company Secretary
Tel: +61 8 81100999
dario@uhyhn.com.au

Australia contact (media):

Financial & Corporate Relations Pty Limited
Tel : +61 2 9235 1666
b.mahoney@fcr.com.au

Singapore contact (media):

WeR1 Consultants Pte Ltd
Tel : +65 6737 4844
maybarza@wer1.net